DelveInsight’s, “COVID-19 Pipeline Insight 2023” report provides comprehensive insights about 400+ companies and 400+ pipeline drugs in the COVID-19 pipeline landscape. It covers the COVID-19 pipeline drug profiles, including clinical and nonclinical stage products. It also covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the COVID-19 Pipeline Report

• DelveInsight’s COVID-19 pipeline report depicts a robust space with 400+ active players working to develop 400+ pipeline therapies for COVID-19 treatment.
• The leading companies working in the COVID-19 Market include Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., TC BioPharm, Syntax for Science, S.L, Shaperon, Renibus Therapeutics, Quercis Pharma, Pharmenterprises, Pharmamel S.L., Orpheris, OPKO Health, Oncotelic Inc., Notitia Biotechnologies Company, Jazz Pharmaceuticals, Ionis Pharmaceuticals, Inotrem, Grifols Therapeutics LLC, Grifols Therapeutics LLC, Globavir Biosciences, Genentech, Inc., FSD Pharma, Faron Pharmaceuticals, Evergreen Therapeutics, Enlivex Therapeutics, Eiger BioPharmaceuticals, Direct Biologics, Debiopharm, Clene Nanomedicine, Chiesi Farmaceutici S.p.A., Cadila Healthcare Limited,  Biotest, BeiGene, Apeiron Biologics, AgelessRx, AbbVie/Apotex, Telios Pharmaceuticals, Rapa Therapeutics, Organicell Regenerative Medicine, Miltenyi Biomedicine, MedRegen LLC, Kiadis Pharma, Kamada, Cellularity Incorporated, Bio-Thera Solutions, 3M, Sironax, Pfizer, Oncovir, Ology Bioservices, Neutrolis, NeoImmune Tech, Natureceuticals Sdn Bhd, Medicine Invention, Kiadis Pharma, Grand Medical, Frontier Biotechnologies, Emergent Biosolutions, Codagenix, Cellenkos, AlloVir, Bausch Health Americas, AiCuris, AgenTus Therapeutics, 4D Pharma, and others.
• Promising COVID-19 Pipeline Therapies in the various stages of development include AZD1222, AZD7442, Plitidepsin 1.5 mg/day, Acalabrutinib, Sarilumab, ZF2001, Bamlanivimab, AT-527, and others.
• September 2023: Guangzhou Patronus Biotech Co., Ltd. announced a study of Phase 3 clinical trials for Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 and ZF2001. The study is a randomized, double-blind, positive control design and 1200 subjects are randomly assigned to LYB001 and positive control groups in a 1:1 ratio to evaluate the safety and immunogenicity as a booster vaccination.
• September 2023: BioNTech SE announced a study of Phase 2 & 3 Clinical Trials for BNT162b2 30mcg. This is a Phase 1/2/3 study in healthy children. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants

 

Request a sample and discover the recent advances in COVID-19 Treatment Drugs @ COVID-19 Pipeline Report

 

In the COVID-19 Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, COVID-19 collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

COVID-19 Overview

Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease causes respiratory illness (like the flu) with symptoms such as a cough, fever, and difficulty breathing.

 

Find out more about COVID-19 Therapeutics Assessment @ COVID-19 Preclinical and Discovery Stage Products

 

COVID-19 Emerging Drugs Profile

• REGN-COV2: Regeneron Pharmaceuticals
• Bucillamine: Revive Therapeutics
• Mupadolimab (CPI-006): Corvus Pharmaceuticals
• VERU‑111: Veru Inc.
• Sarconeos (BIO101): Biophytis
• Leronlimab: CytoDyn
• Tocilizumab: Hoffmann-La Roche

 

COVID-19 Pipeline Therapeutics Assessment

There are approx. 400+ key companies which are developing the COVID-19 therapies. The COVID-19 companies that have their COVID-19 drug candidates in the most advanced stage, i.e. phase III include Regeneron Pharmaceuticals.

 

Learn more about the emerging COVID-19 Pipeline Therapies @ COVID-19 Clinical Trials Assessment

 

Scope of the COVID-19 Pipeline Report

• Coverage- Global
• COVID-19 Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• COVID-19 Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• COVID-19 Companies- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., TC BioPharm, Syntax for Science, S.L, Shaperon, Renibus Therapeutics, Quercis Pharma, Pharmenterprises, Pharmamel S.L., Orpheris, OPKO Health, Oncotelic Inc., Notitia Biotechnologies Company, Jazz Pharmaceuticals, Ionis Pharmaceuticals, Inotrem, Grifols Therapeutics LLC, Grifols Therapeutics LLC, Globavir Biosciences, Genentech, Inc., FSD Pharma, Faron Pharmaceuticals, Evergreen Therapeutics, Enlivex Therapeutics, Eiger BioPharmaceuticals, Direct Biologics, Debiopharm, Clene Nanomedicine, Chiesi Farmaceutici S.p.A., Cadila Healthcare Limited,  Biotest, BeiGene, Apeiron Biologics, AgelessRx, AbbVie/Apotex, Telios Pharmaceuticals, Rapa Therapeutics, Organicell Regenerative Medicine, Miltenyi Biomedicine, MedRegen LLC, Kiadis Pharma, Kamada, Cellularity Incorporated, Bio-Thera Solutions, 3M, Sironax, Pfizer, Oncovir, Ology Bioservices, Neutrolis, NeoImmune Tech, Natureceuticals Sdn Bhd, Medicine Invention, Kiadis Pharma, Grand Medical, Frontier Biotechnologies, Emergent Biosolutions, Codagenix, Cellenkos, AlloVir, Bausch Health Americas, AiCuris, AgenTus Therapeutics, 4D Pharma, and others.
• COVID-19 Pipeline Therapies- AZD1222, AZD7442, Plitidepsin 1.5 mg/day, Acalabrutinib, Sarilumab, ZF2001, Bamlanivimab, AT-527, and others.

 

Dive deep into rich insights for new drugs for COVID-19 Treatment, Visit @ COVID-19 Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. COVID-19: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. REGN-COV2: Regeneron Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. CNM-ZnAg: Clene Nanomedicine
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. SIR1-365: Sironax
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. SB019: Novan
17. Drug profiles in the detailed report…..
18. Inactive Products
19. COVID-19 Key Companies
20. COVID-19 Key Products
21. COVID-19- Unmet Needs
22. COVID-19- Market Drivers and Barriers
23. COVID-19- Future Perspectives and Conclusion
24. COVID-19 Analyst Views
25. COVID-19 Key Companies
26. Appendix

 

For further information on the COVID-19 Pipeline therapeutics, reach out to COVID-19 Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking